Literature DB >> 8496867

Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia.

M Zafarullah1, J P Pelletier, J M Cloutier, J Martel-Pelletier.   

Abstract

The levels of metalloproteases and inhibitor expression in synovial membranes were measured by analyzing mRNA of collagenase, stromelysin, and tissue inhibitor of metalloproteinase (TIMP-1) in this tissue from 20 healthy persons and 20 patients with osteoarthritis (OA). Our results indicated that while most of the normal synovia expressed TIMP-1 mRNA at low levels, very few expressed metalloproteinase mRNA. In contrast 40% of patients with OA expressed a moderate level of collagenase compared to 55 and 80% cases with considerably elevated stromelysin and TIMP-1 mRNA, respectively. The mRNA expression of collagenase (p < 0.032), stromelysin (p < 0.0001) and TIMP-1 (p < 0.008) was significantly higher in OA than in normals. The greater abundance of stromelysin mRNA relative to collagenase indicates differential regulation of the 2 genes. We also demonstrated an association of IL-1 with metalloproteinase gene expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496867

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.

Authors:  Y Yoshihara; H Nakamura; K Obata; H Yamada; T Hayakawa; K Fujikawa; Y Okada
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

2.  Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific.

Authors:  A J Freemont; V Hampson; R Tilman; P Goupille; Y Taiwo; J A Hoyland
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

Review 3.  Articular cartilage and osteoarthrosis. The role of molecular markers to monitor breakdown, repair and disease.

Authors:  L S Lohmander
Journal:  J Anat       Date:  1994-06       Impact factor: 2.610

Review 4.  Matrix metalloproteinase inhibitors: applications in oncology.

Authors:  D Yip; A Ahmad; C S Karapetis; C A Hawkins; P G Harper
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Differential expression patterns of matrix metalloproteinases and their inhibitors during development of osteoarthritis in a transgenic mouse model.

Authors:  H J Salminen; A-M K Säämänen; M N Vankemmelbeke; P K Auho; M P Perälä; E I Vuorio
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

6.  Activation of PPARs α, β/δ, and γ Impairs TGF-β1-Induced Collagens' Production and Modulates the TIMP-1/MMPs Balance in Three-Dimensional Cultured Chondrocytes.

Authors:  Paul-Emile Poleni; Stephanie Etienne; Emilie Velot; Patrick Netter; Arnaud Bianchi
Journal:  PPAR Res       Date:  2010-10-04       Impact factor: 4.964

7.  The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to man.

Authors:  Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Arthritis Res       Date:  2001-11-02

8.  Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor.

Authors:  J G Conway; J A Wakefield; R H Brown; B E Marron; L Sekut; S A Stimpson; A McElroy; J A Menius; J J Jeffreys; R L Clark
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.